FOXA2 and non-small cell lung carcinoma: For instance, FOXA2 was found to be overexpressed at the AFE stage in both models by RET mutations, consistent with its upregulation by KIF5B-RET fusion in NSCLC through RET downstream signaling pathways (Figure 1E and Figure 4C) [55].